An exome-sequencing screen of HER2-positive breast cancer cells asked which mutations track with therapy resistance, implicating an ANAPC4 variant in trastuzumab sensitivity.
Evidence Exome and single-cell targeted sequencing with functional sensitivity assays in BT-474 cells
- ANAPC4 E16K effect is not separated from the concurrent MFSD11 L242I mutation
- no mechanism linking the variant to resistance established
- single lab, single method without isogenic validation